Skip to main content

Table 2 Targeted PAH therapy in patients

From: Monotherapy in patients with pulmonary arterial hypertension at four German PH centres

Baseline

Typical

Atypical

p value

PAH therapy, 0–3 months

n = 86

n = 45

 

 None

10 (11.6%)

4 (8.9%)

0.212

 Monotherapy

49 (57.0%)

34 (75.6%)

 

 Dual therapy

21 (24.4%)

6 (13.3%)

 

 Triple therapy

6 (7.0%)

1 (2.2%)

 
 

n = 76

n = 41

 

 Monotherapy

49 (64.5%)

34 (82.9%)

0.036

 Dual and triple therapy

27 (35.5%)

7 (17.1%)

 

PAH therapy, 4–8 months

n = 83

n = 42

 

 Monotherapy

43 (51.8%)

29 (69.0%)

0.119

 Dual therapy

33 (39.8%)

9 (21.4%)

 

 Triple therapy

7 (8.4%)

4 (9.5%)

 
 

n = 83

n = 42

 

Monotherapy

43 (51.8%)

29 (69.0%)

0.065

Dual and triple therapy

40 (48.2%)

13 (31.0%)

 

PAH therapy, 9–15 months

n = 72

n = 39

 

 Monotherapy

30 (41.7%)

20 (51.3%)

0.576

 Dual therapy

35 (48.6%)

15 (38.5%)

 

 Triple therapy

7 (9.7%)

4 (10.3%)

 
 

n = 72

n = 39

 

Monotherapy

30 (41.7%)

20 (51.3%)

0.331

Dual and triple therapy

42 (58.3%)

19 (48.7%)

 
  1. Data are given as percentages